Status and problems of legislative regulation of circulation and consumption of nicotinecontaining goods

Objective: to study the current state of the legislative regulation of nicotine-containing products turnover and consumption; to identify the main problems in this area and to suggest possible ways to solve them. Methods: the methodological basis of the work is interdisciplinary, systematic and comparative approaches, as well as general scientific methods of cognition: induction and deduction, analysis and synthesis, abstraction, observation, and empirical methods. Results: the trend of the recent years has been the transition from the use of traditional nicotine products to electronic means of nicotine delivery, which is confirmed by a large amount of data and is explained by a number of advantages. However, the potential threats from the use of alternative nicotine-containing products have not been sufficiently studied and are accompanied by a weak legal framework for their use. In the article, the author considers the features of state regulation of nicotine-containing products that are not related to tobacco products, and analyzes the contradictions and shortcomings of legislative solutions in this area. The main consequences of equating nicotine-containing products with tobacco products are systematized, both in terms of the impact on the nicotine use restriction and of referring them to excisable products. Legislative solutions concerning the use of food nicotine-containing products and products intended for chewing, sucking, and sniffing are also analyzed. Scientific novelty: recommendations are proposed to eliminate the problems identified during the analysis of the regulation of the nicotine-containing products turnover and use. The presented measures are aimed at mitigating the regulatory impact of the nicotine-containing products use while reducing the negative impact of such products on public health.Practical significance: the provisions and conclusions presented in this paper can be used in the development of regulatory legal acts aimed at amending the legislation regulating the nicotine-containing products turnover and consumption

ПРОГНОЗИРОВАНИЕ СЕБЕСТОИМОСТИ ПОСТРОЙКИ СУДНА С ИСПОЛЬЗОВАНИЕМ АППАРАТА ТЕОРИИ НЕЧЕТКИХ МНОЖЕСТВ

In order to take a rational decision about construction of a ship it is necessary to have an adequate predictive estimate of a construction cost. Traditional forecasting methods do not provide the required level of reliability of a shipyard’s cost estimates. The method of cost forecasting based on fuzzy logic system is proposed. This method has several advantages, including: use of fuzzy initial information for forecasting; increase of the result’s validity due to the potential of use all relevant information for forecasting. In view of the aforesaid it increases the validity of management decisions and has a positive impact on the overall economic sustainability of an enterprise.Для принятия рационального решения о постройке судна необходимо иметь адекватную прогнозную оценку себестоимости. Традиционные методы прогнозирования не позволяют получить оценку затрат верфи с требуемой степенью достоверности.Предложен подход к прогнозированию затрат, основанный на системе нечеткого логического вывода. Данный подход обладает рядом преимуществ, среди которых: использование для целей прогнозирования нечеткой исходной информации; повы­шение обоснованности результата за счет возможности использования в процессе прогнозирования всей релевантной информации. Это позволит повысить обоснованность принимаемых управленческих решений, положительно отразится на общей экономической устойчивости предприятия

Study of the graphene oxide nanoparticles effect on luminol-dependent chemiluminescence of human leukocytes

Graphene and its derivatives are increasingly used in biomedical research. Therefore, the mechanisms and consequences of the interaction of graphene nanoparticles with living objects are intensively studied. The immune system is involved in protecting the body and regulating its functions, so the question of the effect of graphene and its derivatives on immune cells is crucial. The specific response of monocytes, macrophages, and neutrophils to a stimulus is to increase the production of reactive oxygen species (ROS). Published data on graphene oxide (GO) and polyethylene glycol-modified graphene oxide (GO-PEG) effects on peripheral blood leukocytes are scarce and contradictory. It is due to variations in objects and conditions of study, along with the difference in particle concentrations. Thus, it was essential to evaluate the GO and GO-PEG effect on ROS production by human leukocytes. Our study aimed at the effect of particles of unmodified and PEG-modified graphene oxide (GO and GO-PEG) on the ROS production by peripheral blood leukocytes in not-stimulated and stimulated luminoldependent chemiluminescence (LCL) tests. ROS production was stimulated by opsonized zymosan (OZ). A hydrogen peroxide-luminol system was used for assessing the independent effect of GO nanoparticles on the quenching of ROS luminescence. Pristine GO (Ossila, Great Britain) nanoparticles were PEG-modified (GO-PEG). The average size of the GO flakes was 1-5 µm, the GO-PEG-flakes 569±14 nm, and the amount of PEG covering was ~ 20%. Nanoparticles were used at concentrations of 5; 2.5; 1.25 µg/ml. It has been established that GO-PEG nanoparticles in concentrations of 2.5 and 5 µg/ml suppressed ROS production in the spontaneous LCL test. At the same time, the GO effects showed a visible but a not significant tendency to inhibition of LCL. Similar results were obtained in the stimulated LCL test. However, when analyzing the process kinetics, both GO-PEG and GO decreased the ROS production, but mainly in the first minutes of the test. When analyzing the quenching effect of the LCL reaction in a cell-free system, there was no significant effect of GO and GO-PEG nanoparticles. Thus, the general vector of the obtained effects was associated with the suppression of ROS production. GO-PEG ROS-decreasing effects were more pronounced in comparison with unmodified GO. In general, we have confirmed the antioxidant effects of GO and GO-PEG using the LCL method. We can assume that in addition to the actual antioxidant effect of graphene nanoparticles, ROS production decreases due to the rapid GO uptake and blocking of several intracellular signals that induce an oxidative burst

Genome Characterization of a Pathogenic Porcine Rotavirus B Strain Identified in Buryat Republic, Russia in 2015

Citation: Alekseev, K.P.; Penin, A.A.; Mukhin, A.N.; Khametova, K.M.; Grebennikova, T.V.; Yuzhakov, A.G.; Moskvina, A.S.; Musienko, M.I.; Raev, S.A.; Mishin, A.M.; Kotelnikov, A.P.; Verkhovsky, O.A.; Aliper, T.I.; Nepoklonov, E.A.; Herrera-Ibata, D.M.; Shepherd, F.K.; Marthaler, D.G. Genome Characterization of a Pathogenic Porcine Rotavirus B Strain Identified in Buryat Republic, Russia in 2015. Pathogens 2018, 7, 46.An outbreak of enteric disease of unknown etiology with 60% morbidity and 8% mortality in weaning piglets occurred in November 2015 on a farm in Buryat Republic, Russia. Metagenomic sequencing revealed the presence of rotavirus B in feces from diseased piglets while no other pathogens were identified. Clinical disease was reproduced in experimentally infected piglets, yielding the 11 RVB gene segments for strain Buryat15, with an RVB genotype constellation of G12-P[4]-I13-R4-C4-M4-A8-N10-T4-E4-H7. This genotype constellation has also been identified in the United States. While the Buryat15 VP7 protein lacked unique amino acid differences in the predicted neutralizing epitopes compared to the previously published swine RVB G12 strains, this report of RVB in Russian swine increases our epidemiological knowledge on the global prevalence and genetic diversity of RVB

Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis

Cardiac disease in diabetes mellitus and in the metabolic syndrome consists of both vascular and myocardial abnormalities. The latter are characterised predominantly by diastolic dysfunction, which has been difficult to evaluate in spite of its prevalence. While traditional Doppler echocardiographic parameters enable only semiquantitative assessment of diastolic function and cannot reliably distinguish perturbations in loading conditions from altered diastolic functions, new technologies enable detailed quantification of global and regional diastolic function. The most readily available technique for the quantification of subclinical diastolic dysfunction is tissue Doppler imaging, which has been integrated into routine contemporary clinical practice, whereas cine magnetic resonance imaging (CMR) remains a promising complementary research tool for investigating the molecular mechanisms of the disease. Diastolic function is reported to vary linearly with age in normal persons, decreasing by 0.16 cm/s each year. Diastolic function in diabetes and the metabolic syndrome is determined by cardiovascular risk factors that alter myocardial stiffness and myocardial energy availability/bioenergetics. The latter is corroborated by the improvement in diastolic function with improvement in metabolic control of diabetes by specific medical therapy or lifestyle modification. Accordingly, diastolic dysfunction reflects the structural and metabolic milieu in the myocardium, and may allow targeted therapeutic interventions to modulate cardiac metabolism to prevent heart failure in insulin resistance and diabetes

Increased Systemic Th17 Cytokines Are Associated with Diastolic Dysfunction in Children and Adolescents with Diabetic Ketoacidosis

Diastolic dysfunction suggestive of diabetic cardiomyopathy is established in children with T1DM, but its pathogenesis is not well understood. We studied the relationships of systemic inflammatory cytokines/chemokines and cardiac function in 17 children with T1DM during and after correction of diabetic ketoacidosis (DKA). Twenty seven of the 39 measured cytokines/chemokines were elevated at 6–12 hours into treatment of DKA compared to values after DKA resolution. Eight patients displayed at least one parameter of diastolic abnormality (DA) during acute DKA. Significant associations were present between nine of the cytokine/chemokine levels and the DA over time. Interestingly, four of these nine interactive cytokines (GM-CSF, G-CSF, IL-12p40, IL-17) are associated with a Th17 mediated cell response. Both the DA and CCL7 and IL-12p40, had independent associations with African American patients. Thus, we report occurrence of a systemic inflammatory response and the presence of cardiac diastolic dysfunction in a subset of young T1DM patients during acute DKA

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.